HPV infection and vaccination in Systemic Lupus Erythematosus patients: What we really should know

Pediatric Rheumatology

Volumn 14, Issue 1, 2016, Pages

  Grein, Ingrid Herta Rotstein ^a,b   Groot, Noortje ^a,c   Lacerda, Marcela Ignacchiti ^d   Wulffraat, Nico ^a   Pileggi, Gecilmara ^e  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b HOSPITAL PEQUENO PRÍNCIPE   (Brazil)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^d Institute of Dermatology of Rio de Janeiro   (Brazil)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cervical cancer; Cervical dysplasia; HPV; Human papillomavirus infection; Immunosuppression; SLE; Systemic lupus erythematosus; Vaccines

Indexed keywords

BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; LIVE VACCINE; MYCOPHENOLATE MOFETIL; PNEUMOCOCCUS VACCINE; PREDNISOLONE; RITUXIMAB; VARICELLA ZOSTER VACCINE; WART VIRUS VACCINE;

ANTIBODY TITER; CONDYLOMA ACUMINATUM; HUMAN; IMMUNOCOMPROMISED PATIENT; INCIDENCE; INFECTION RISK; PAPILLOMAVIRUS INFECTION; PATIENT SAFETY; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; UTERINE CERVIX CANCER; UTERINE CERVIX DISEASE; VENOUS THROMBOEMBOLISM; WART VIRUS; ALPHAPAPILLOMAVIRUS; COMPLICATION; GLOBAL HEALTH; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS; PRACTICE GUIDELINE; PROCEDURES; VACCINATION;

ALPHAPAPILLOMAVIRUS; GLOBAL HEALTH; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; VACCINATION;

EID: 85007597357     PISSN: None     EISSN: 15460096     Source Type: Journal    
DOI: 10.1186/S12969-016-0072-X     Document Type: Review

References (70)

1. Silva CA, Aikawa NE, Bonfa E. Vaccinations in juvenile chronic inflammatory diseases: an update. Nat Rev Rheumatol. 2013;9(9):532-43.
2. Westra J et al. Vaccination of patients with autoimmune inflammatory rheumatic diseases. Nat Rev Rheumatol. 2015;11(3):135-45.
3. Bijl M et al. Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessment. Autoimmun Rev. 2012;11(8): 572-6.
4. Conti F, Rezai S, Valesini G. Vaccination and autoimmune rheumatic diseases. Autoimmun Rev. 2008;8(2):124-8.
5. Murdaca G et al. Influenza and pneumococcal vaccinations of patients with systemic lupus erythematosus: current views upon safety and immunogenicity. Autoimmun Rev. 2014;13(2):75-84.
6. Guthridge JM et al. Herpes zoster vaccination in SLE: a pilot study of immunogenicity. J Rheumatol. 2013;40(11):1875-80.
7. Gupta N et al. Review article: BK virus in systemic lupus erythematosus. Pediatr Rheumatol Online J. 2015;13:34.
8. Rahier JF et al. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology (Oxford). 2010;49(10):1815-27.
9. Akikusa JD, Crawford NW. Vaccination in paediatric rheumatology. Curr Rheumatol Rep. 2014;16(8):432.
10. Dell' Era L et al. Vaccination of children and adolescents with rheumatic diseases. Rheumatology (Oxford). 2011;50(8):1358-65.
11. Groot N, Heijstek MW, Wulffraat NM. Vaccinations in paediatric rheumatology: an update on current developments. Curr Rheumatol Rep. 2015;17(7):46.
12. Aytac MB et al. Hepatitis B vaccination in juvenile systemic lupus erythematosus. Clin Exp Rheumatol. 2011;29(5):882-6.
13. Kuruma KA et al. Safety and efficacy of hepatitis B vaccine in systemic lupus erythematosus. Lupus. 2007;16(5):350-4.
14. Petrosky E et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64(11):300-4.
15. Pils S, Joura EA. From the monovalent to the nine-valent HPV vaccine. Clin Microbiol Infect. 2015;21(9):827-33.
16. Lees BF, Erickson BK, Huh WK. Cervical Cancer Screening: Evidence Behind the Guidelines. Am J Obstet Gynecol. 2015 doi:10.1016/j.ajog.2015.10.147.
17. Pellegrino P, Radice S, Clementi E. Immunogenicity and safety of the human papillomavirus vaccine in patients with autoimmune diseases: a systematic review. Vaccine. 2015;33(30):3444-9.
18. Lube G et al. Condyloma acuminatum by human papilloma virus infection in childhood-systemic lupus erythematosus patients. Acta Reumatol Port. 2014;39(2):182-7.
19. Lyrio LD et al. Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus. Rheumatol Int. 2013;33(2): 335-40.
20. Santana IU et al. Systemic lupus erythematosus, human papillomavirus infection, cervical pre-malignant and malignant lesions: a systematic review. Clin Rheumatol. 2011;30(5):665-72.
21. Cibere J, Sibley J, Haga M. Systemic lupus erythematosus and the risk of malignancy. Lupus. 2001;10(6):394-400.
22. Liu H et al. Meta-analysis of systemic lupus erythematosus and the risk of cervical neoplasia. Rheumatology (Oxford). 2011;50(2):343-8.
23. Zard E et al. Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: a meta-analysis of the literature. Autoimmun Rev. 2014;13(7):730-5.
24. Tam LS et al. Natural history of cervical papilloma virus infection in systemic lupus erythematosus-a prospective cohort study. J Rheumatol. 2010;37(2): 330-40.
25. Nath R et al. High risk of human papillomavirus type 16 infections and of development of cervical squamous intraepithelial lesions in systemic lupus erythematosus patients. Arthritis Rheum. 2007;57(4):619-25.
26. Klumb EM et al. Are women with lupus at higher risk of HPV infection? Lupus. 2010;19(13):1485-91.
27. Bateman H et al. Increased cervical dysplasia in intravenous cyclophosphamide-treated patients with SLE: a preliminary study. Lupus. 2000;9(7):542-4.
28. Heijstek MW et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. 2011;70(10):1704-12.
29. Heijstek MW et al. Vaccination in paediatric patients with auto-immune rheumatic diseases: a systemic literature review for the European League against Rheumatism evidence-based recommendations. Autoimmun Rev. 2011;11(2):112-22.
30. Aikawa NE et al. Glucocorticoid: major factor for reduced immunogenicity of 2009 influenza A (H1N1) vaccine in patients with juvenile autoimmune rheumatic disease. J Rheumatol. 2012;39(1):167-73.
31. Campos LM et al. High disease activity: an independent factor for reduced immunogenicity of the pandemic influenza a vaccine in patients with juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2013;65(7):1121-7.
32. Ogimi C et al. Immunogenicity of influenza vaccine in children with pediatric rheumatic diseases receiving immunosuppressive agents. Pediatr Infect Dis J. 2011;30(3):208-11.
33. Kanakoudi-Tsakalidou F et al. Influenza vaccination in children with chronic rheumatic diseases and long-term immunosuppressive therapy. Clin Exp Rheumatol. 2001;19(5):589-94.
34. Barbosa CM et al. Immune response and tolerability of varicella vaccine in children and adolescents with systemic lupus erythematosus previously exposed to varicella-zoster virus. Clin Exp Rheumatol. 2012;30(5):791-8.
35. Ault KA. Epidemiology and natural history of human papillomavirus infections in the female genital tract. Infect Dis Obstet Gynecol. 2006;2006 Suppl:40470.
36. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol. 2005;32 Suppl 1:S16-24.
37. Erickson BK, Alvarez RD, Huh WK. Human papillomavirus: what every provider should know. Am J Obstet Gynecol. 2013;208(3):169-75.
38. Wheeler CM. Natural history of human papillomavirus infections, cytologic and histologic abnormalities, and cancer. Obstet Gynecol Clin North Am. 2008;35(4):519-36. vii.
39. de Martel C et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13(6):607-15.
40. Villain P et al. European Code against Cancer 4th Edition: Infections and Cancer. Cancer Epidemiol. 2015. 39S (2015) S120-S138
41. Park H et al. Rate of vertical transmission of human papillomavirus from mothers to infants: relationship between infection rate and mode of delivery. Virol J. 2012;9:80.
42. Rombaldi RL et al. Transplacental transmission of Human Papillomavirus. Virol J. 2008;5:106.
43. Rombaldi RL et al. Perinatal transmission of human papilomavirus DNA. Virol J. 2009;6:83.
44. Chatzistamatiou, K., A. Sotiriadis, and T. Agorastos, Effect of mode of delivery on vertical human papillomavirus transmission-A meta-analysis. J Obstet Gynaecol, 2016. 36(1): p. 10-4.
45. Tarka A et al. Risk assessment of chronic HPV HR infection in babies who contacted the virus in the perinatal period. Ginekol Pol. 2011;82(9):664-9.
46. Smith JS et al. Age-specific prevalence of infection with human papillomavirus in females: a global review. J Adolesc Health. 2008;43(4 Suppl):S5-25, S25 e1-41.
47. Solomon D et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA. 2002;287(16):2114-9.
48. Nayar R, Wilbur DC. The Pap Test and Bethesda 2014: "The reports of my demise have been greatly exaggerated. (after a quotation from Mark Twain)". J Low Genit Tract Dis. 2015;19(3):175-84.
49. Ferlay J et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86.
50. Schiffman M et al. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst. 2011;103(5):368-83.
51. Armaroli P et al. European Code against Cancer, 4th Edition: Cancer screening. Cancer Epidemiol, 2015. 39S (2015) S139-S152.
52. Thaxton L, Waxman AG. Cervical cancer prevention: immunization and screening 2015. Med Clin North Am. 2015;99(3):469-77.
53. Harper DM et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364(9447):1757-65.
54. Harper DM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367(9518):1247-55.
55. The FUTURE II Study Group Luisa L. Villa; Gonzalo Perez; Susanne; Krüger Kjær; Jorma Paavonen; Matti Lehtinen; Nubia Muñoz; Kristján Sigurdsson; Mauricio Hernandez-Avila; Ole Eric Iversen; Steinar Thoresen; Patricia J. García; Slawomir Majewski; Eng Hseon Tay; F. Xavier Bosch; Joakim Dillner; Sven-Eric Olsson; Kevin A. Ault; Darron R. Brown; Daron G. Ferris; Laura A. Koutsky; Robert J. Kurman; Evan R. Myers; Eliav Barr, John Boslego, Janine Bryan, Mark T. Esser, Teresa M. Hesley, Micki Nelson, Radha Railkar, Margaret James, Carlos Sattler, Frank J. Taddeo, Annemarie R. Thornton, and Scott C. Vuocolo Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis. 2007;196(10):1438-46.
56. Dillner J et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010;341:c3493.
57. Committee on Adolescent Health Care Immunization Expert Work Group Committee Opinion No. 641: Human Papillomavirus Vaccination. Obstet Gynecol. 2015. 126(3): e38-43.
58. Joura EA et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015;372(8):711-23.
59. World Health Organization (WHO) Human papillomavirus vaccines: WHO position paper, October 2014-Recommendations. Vaccine. 2015;33(36): 4383-4.
60. Drolet M et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and metaanalysis. Lancet Infect Dis. 2015;15(5):565-80.
61. Jayasinghe YL et al. Human papillomavirus in adolescents: lessons learned from decades of evaluation. J Paediatr Child Health. 2013;49(2):99-104.
62. Slade BA et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009;302(7):750-7.
63. Arnheim-Dahlstom L et al. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ. 2013;347.
64. Esposito S et al. Immunogenicity, safety and tolerability of a bivalent human papillomavirus vaccine in adolescents with juvenile idiopathic arthritis. Expert Rev Vaccines. 2014;13(11):1387-93.
65. Jacobson DL et al. Immunogenicity and tolerability to human papillomavirus-like particle vaccine in girls and young women with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(7):1441-9.
66. Mok CC et al. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-control study. Ann Rheum Dis. 2013;72(5):659-64.
67. Soybilgic A et al. Safety and immunogenicity of the quadrivalent HPV vaccine in female Systemic Lupus Erythematosus patients aged 12 to 26 years. Pediatr Rheumatol Online J. 2013;11:29.
68. Heijstek MW et al. Immunogenicity of the bivalent human papillomavirus vaccine in adolescents with juvenile systemic lupus erythematosus or juvenile dermatomyositis. J Rheumatol. 2013;40(9):1626-7.
69. Heijstek MW et al. Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: a prospective controlled observational cohort study. Ann Rheum Dis. 2014;73(8):1500-7.
70. Pellegrino P et al. Human papillomavirus vaccine in patients with systemic lupus erythematosus. Epidemiology. 2014;25(1):155-6.